Results 271 to 280 of about 37,267 (288)

Systemic AL-amyloidosis

The Lancet, 2014
A 62-year-old man came to our outpatient clinic with purpura on his eyelids. 7 months before, periocular purpura appeared after a minimal trauma. These lesions did not resolve for months. He also reported fatigue over the previous 6 months. On examination pinch purpura between smooth waxy papules were found (fi gure).
Barbara C. Böckle, N Sepp
openaire   +2 more sources

Primary generalized AL amyloidosis

Arkhiv patologii, 2021
The paper describes an autopsy observation of a 71-year-old male with primary generalized AL amyloidosis lasting about 4 months after its manifestation to the onset of death from hepatic and renal failure. Total damage to the liver and spleen, as well as amyloid deposits in the kidneys, adrenal glands, and pancreas were noted.
B B Saltykov, E A Kogan, P V Atanov
openaire   +3 more sources

AL Amyloidosis

New England Journal of Medicine
AL Amyloidosis A 58-year-old man presented with a 2-year history of eyelid lesions and several months of weight loss and fatigue. Scattered periorbital petechiae and purpura were noted, as well as coalescing, waxy papules on the eyelids.
Miguel Mansilla Polo, Margarita Llavador-Ros   +1 more
openaire   +3 more sources

AL amyloidosis enhances development of amyloid A amyloidosis

British Journal of Dermatology, 2007
Contains fulltext : 52125.pdf (Publisher’s version ) (Closed access)
Hilst, J.C.H. van der, Meer, J.W.M. van der, Drenth, J.P.H., Simon, A.   +3 more
openaire   +3 more sources

Macroglossia – not always AL amyloidosis

Amyloid, 2010
Abstract Abstract 5007 Introduction: Amyloidosis is characterized by extracellular deposition of abnormal insoluble fibrillar proteins. The two most frequent systemic amyloidoses are the light-chain (AL amyloidosis) and familial transthyretin (ATTR) forms.
John L. Berk, David C. Seldin, Carl O'Hara, Martha Skinner, J. Mark Sloan, Vaishali Sanchorawala, Andrew J. Cowan   +6 more
openaire   +4 more sources

Diagnosis and Treatment of AL Amyloidosis

Drugs, 2023
Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light chain forming amyloid deposits in tissue. The heart and kidney are the major organs affected, but all others, with the exception of the CNS, can be involved. The disease is rapidly progressive, and it is still diagnosed late.
Giovanni Palladini, Paolo Milani
openaire   +2 more sources

Management of AL amyloidosis in 2021+

Amyloid, 2021
Pallidini et al. in their review article ‘Management of AL Amyloidosis in 2020’ detail the therapeutic options for patients with this disorder [1].
openaire   +3 more sources

Primary amyloidosis (AL) in families

American Journal of Hematology, 1986
AbstractWe report the occurrence of immunoglobulin‐related amyloidosis (AL) in three separate families, each family having two members affected. None of the six patients had evidence to suggest the presence of familial amyloidosis (AF). Previously, immunoglobulin‐related amyloidosis (AL) was considered to be a sporadic disease process.
Robert A. Kyle, John P. Garton, Morie A. Gertz   +2 more
openaire   +2 more sources

Sudden Death by AL Amyloidosis

American Journal of Forensic Medicine & Pathology, 2023
Abstract We report the case of a young female that died due to systemic amyloidosis.
Christian, Perez, Kristy, Waite
openaire   +2 more sources

The epidemiology of AL and AA amyloidosis

Baillière's Clinical Rheumatology, 1994
The limited available epidemiological information on AL amyloidosis suggests that there may be differences between population-based studies and case series data with respect to variables such as age and racial patterns. Much more work in this area is required before specific aetiologic hypotheses can be tested.
Robert W. Simms, Alan S. Cohen, Marianne N. Prout   +2 more
openaire   +3 more sources